Paradigm Biopharmaceuticals is riding on a make‑or‑break moment as its osteoarthritis injection Zilosul moves through late-stage testing and awaits a key US regulator decision. If it works and gets cleared, it could offer a new option beyond today’s pain-focused treatments—but any trial or approval setback could quickly change the outlook.Read more